腹腔、静脉双途径化疗治疗卵巢上皮癌的临床观察  

Clinical observation on Combined intraperitoneal and intravenous chemotherapy in the treatment of epithelial ovarian cancer

作　　者：顾汉刚[1] 杨佩芳[1] 朱小霞[1] 李文军[1] 

机构地区：[1]江苏大学附属医院肿瘤治疗中心,镇江212001

出　　处：《陕西医学杂志》2004年第2期118-120,共3页Shaanxi Medical Journal

摘　　要：目的 :观察不同途径给药对卵巢上皮癌化疗疗效的影响。方法 :72例卵巢上皮癌患者均采用 CAP方案化疗 ,其中 A组环磷酰胺、阿霉素 (或吡喃阿霉素 )经静脉滴注 ,顺铂经腹腔灌注 ,B组则全部经静脉滴注。间隔 3～ 4周 ,共 6～ 8个疗程。结果 :A组治疗总有效率 89.47% ( CR65 .79% + PR2 3.69% )。腹水得到有效控制。B组总有效率 67.65 % ( 4 7.0 6% + 2 0 .5 9% )。两组比较有显著差异。两组 3年生存率分别为 47.37%、44.1 2 % ,A组高于 B组 ,但差异不显著。结论 :顺铂腹腔灌注可减轻药物的副反应 ,提高有效率 ,改善患者生存质量 ,但对提高 3年生存率的意义尚不肯定。Objective: To investigate the effects of different route of medication on the chemotherapeutic results for ovarian cancer. Methods: 72 patients with epithelial ovarian cancer collected from June,1996 to January,2000 in our hospital were treated with CAP regime and randomly divided into two groups. The patients in group A were treated with CTX,ADM(or THP) through intravenous route,while DDP through intraperitoneal route. The patients in group B were treated with the same drugs through intravenous route. The overall therapy lasted for 6 to 8 courses of treatment with intervals of 3～4 weeks. Results:The total effective rate in group A was 89.47%(CR65.79%+PR23.69%).Ascitic fluid was effectively controlled. The total effective rate in group B was 67.65%(47.06%+20.59%) and there was significant difference between them. 3 year survival rate in two groups was 47.37% and 44.12% respectively and there was no significant difference. Conclusion: The delivery of DDP intraperitoneally can reduce the side effects and increase clinical effective rate,as well as improve the patients' life quality,but its effects on the 3 year survival rate is not sure.

关 键 词：卵巢上皮癌 临床观察 生存质量 顺铂 静脉滴注 腹腔灌注 化学疗法 

分 类 号：R737.31[医药卫生—肿瘤] R730.53[医药卫生—临床医学]